Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H44O3 |
Molecular Weight | 452.6686 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC=C)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=AHMMSNQYOPMLSX-CNQKSJKFSA-N
InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
DescriptionSources: https://www.drugs.com/vet/equipoise.html
Sources: https://www.drugs.com/vet/equipoise.html
Boldenone (INN, BAN), also known as Δ1-testosterone, 1-dihydrotestosterone, or androsta-1,4-dien-3-one-17β-ol (train name Equipoise) is a long-acting injectable anabolic agent for horses, supplied in a vial providing 50 mg boldenone undecylenate per mL in sesame oil with 3% (w/v) benzyl alcohol as a preservative. The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis increases appetite and stimulates the release of erythropoietin in the kidneys. Boldenone was synthesized in an attempt to create a long-acting injectable methandrostenolone (Dianabol), for androgen deficiency disorders. Boldenone acts similar to methandrostenolone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and all the associated progestogenic side effects. Equipoise (Boldenone Undecylenate Injection) is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and overexertion. Boldenone improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized. Boldenone should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases, and traumatic injuries.
CNS Activity
Originator
Sources: https://www.google.com/patents/US2962422
Curator's Comment: # Pfizer & Co C
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11252818 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Equipoise Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Regulation of the epididymal glutathione peroxidase-like protein in the mouse: dependence upon androgens and testicular factors. | 1992 Nov |
|
Transformations of testosterone and related steroids in Absidia glauca culture. | 2003 |
|
A new bacterial steroid degradation gene cluster in Comamonas testosteroni TA441 which consists of aromatic-compound degradation genes for seco-steroids and 3-ketosteroid dehydrogenase genes. | 2003 Aug |
|
Transformations of testosterone and related steroids by Botrytis cinerea. | 2003 Jan |
|
Dihydrotestesterone induction of EPHB2 expression in the female genital tubercle mimics male pattern of expression during embryogenesis. | 2003 Oct |
|
Biotransformation of (+)-androst-4-ene-3,17-dione. | 2004 Dec |
|
Histopathological effects of boldenone in cattle. | 2004 Mar |
|
Complete 1H and 13C NMR spectral assignment of 17-hydroxy epimeric sterols with planar A or A and B rings. | 2004 Mar |
|
Confirmatory analysis of 17beta-boldenone, 17alpha-boldenone and androsta-1,4-diene-3,17-dione in bovine urine, faeces, feed and skin swab samples by liquid chromatography-electrospray ionisation tandem mass spectrometry. | 2004 Mar 5 |
|
Production of androgens by microbial transformation of progesterone in vitro: a model for androgen production in rivers. | 2004 Nov |
|
Fetal alcohol exposure alters neurosteroid levels in the developing rat brain. | 2004 Sep |
|
Detection of endogenous boldenone in the entire male horses. | 2004 Sep 5 |
|
ADD, AED, alpha-boldenone and epitestosterone neo formation in calf faeces: preliminary results. | 2005 Aug |
|
Detection, quantification and confirmation of anabolic steroids in equine plasma by liquid chromatography and tandem mass spectrometry. | 2005 Dec 27 |
|
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. | 2005 Sep 8 |
|
Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry. | 2006 Apr |
|
17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. | 2006 Aug 20 |
|
Neoformation of boldenone and related steroids in faeces of veal calves. | 2006 Feb |
|
Dehydroepiandrosterone decreases while cortisol increases in vitro growth and viability of Entamoeba histolytica. | 2006 Feb |
|
Effects of chronic exposure to sodium arsenite on hypothalamo-pituitary-testicular activities in adult rats: possible an estrogenic mode of action. | 2006 Feb 16 |
|
Winter profile of plasma sex steroid levels in free-living male western diamond-backed rattlesnakes, Crotalus atrox (Serpentes: Viperidae). | 2006 Oct |
|
Excretion profile of boldenone and its metabolites after oral administration to veal calves. | 2007 Apr 25 |
|
Rapid screening of doping agents in human urine by vacuum MALDI-linear ion trap mass spectrometry. | 2007 Aug 1 |
|
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. | 2007 Aug 1 |
|
Development of an immunosensor for the detection of testosterone in bovine urine. | 2007 Jan 30 |
|
Phytosterol consumption and the anabolic steroid boldenone in humans: a hypothesis piloted. | 2007 Jul |
|
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. | 2007 Jun 1 |
|
Survey of nutritional supplements for selected illegal anabolic steroids and ephedrine using LC-MS/MS and GC-MS methods, respectively. | 2007 Mar |
|
An in vitro study on metabolism of 17beta-boldenone and boldione using cattle liver and kidney subcellular fractions. | 2007 Mar 14 |
|
Formation of boldenone and boldenone-analogues by maggots of Lucilia sericata. | 2007 Mar 14 |
|
Pathology of the testicle and sex accessory glands following the administration of boldenone and boldione as growth promoters in veal calves. | 2007 Nov |
|
A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists. | 2007 Nov |
|
Boldenone, boldione, and milk replacers in the diet of veal calves: the effects of phytosterol content on the urinary excretion of boldenone metabolites. | 2007 Oct 3 |
|
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. | 2008 Aug 28 |
|
Nutritional supplements cross-contaminated and faked with doping substances. | 2008 Jul |
|
Boldenone, testosterone and 1,4-androstadiene-3,17-dione determination in faeces from horses, untreated and after administration of androsta-1,4-diene-3,17-dione (boldione). | 2008 Jun |
|
Multivariate optimization of a derivatisation procedure for the simultaneous determination of nine anabolic steroids by gas chromatography coupled with mass spectrometry. | 2008 May 9 |
|
[Determination of eleven steroid hormones in animal muscle tissues and eggs using ultra-performance liquid chromatography-tandem mass spectrometry]. | 2008 Nov |
|
The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. | 2008 Nov 28 |
|
Quantification of 19-nortestosterone sulphate and boldenone sulphate in urine from male horses using liquid chromatography/tandem mass spectrometry. | 2008 Oct |
|
Simultaneous measurement of boldenone (alpha and beta), ADD, testosterone, epitestosterone and AED in bovine faeces. | 2008 Sep |
|
Acupuncture and exercise restore adipose tissue expression of sympathetic markers and improve ovarian morphology in rats with dihydrotestosterone-induced PCOS. | 2009 Apr |
|
Validation and application of a yeast bioassay for screening androgenic activity in calf urine and feed. | 2009 Apr 1 |
|
Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels. | 2009 Aug |
|
17alpha- and 17beta-boldenone 17-glucuronides: synthesis and complete characterization by 1H and 13C NMR. | 2009 Feb |
|
Evaluation of equine urine reactivity towards phase II metabolites of 17-hydroxy steroids by liquid chromatography/tandem mass spectrometry. | 2009 Jan |
|
Characterization of SV-40 Tag rats as a model to study prostate cancer. | 2009 Jan 26 |
|
Sudden unexpected death in a female fitness athlete, with a possible connection to the use of anabolic androgenic steroids (AAS) and ephedrine. | 2009 Jan 30 |
|
Criteria to distinguish between natural situations and illegal use of boldenone, boldenone esters and boldione in cattle 2. Direct measurement of 17beta-boldenone sulpho-conjugate in calf urine by liquid chromatography--high resolution and tandem mass spectrometry. | 2009 Oct |
|
Analysis of anabolic steroids in hair: time courses in guinea pigs. | 2009 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/equipoise.html
The dosage for horses is 0.5 mg per pound of body weight intramuscularly. Treatment may be repeated at three week intervals.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11252818
The rhAR preparation was diluted 150 in assay buffer (5 mM Na2HP04, 150 mM NaCl, pH 7.2, containing 0.16% w/v protease inhibitor mix and 0.1% bovine serum albumin). Aliquots of 0.5 mL were incubated at 04°C for 16 hours with a constant amount of 0.4 nM 3H-DHT and in the presence or absence of increasing concentrations of Boldenone . DHT was used in all experiments as standard. To separate bound and free ligand, the receptor preparation was incubated with 100 mkL of dextrancoated charcoal (4%) charcoal and 0.4% dextran in assay buffer) for 5 min before centrifugation at 2000 x g for 15 min at 4°C. 0.4 mL of the supernatant was transferred into scintillation vials, mixed with 3 mL Xylofluor and counted. Specific binding represents the relative difference of total binding and non specific binding observed in the presence of a 250 fold surplus of unlabelled DHT.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2597
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB125939
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
DB14639
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
13103-34-9
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106059
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
Boldenone undecylenate
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
236-024-5
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
DTXSID00156854
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
100000151640
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
C83559
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
2289409
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
11954310
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
ZS6D2ITA30
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY | |||
|
C001371
Created by
admin on Fri Dec 15 15:33:29 GMT 2023 , Edited by admin on Fri Dec 15 15:33:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD